Rethinking Fill-Finish To Reduce API Loss In Early Development

By James Fraczek, Associate Director, Pace® Life Sciences

In early-stage drug development, Active Pharmaceutical Ingredient (API) supply is frequently one of the most constrained and valuable assets. Despite its scarcity, material loss during the fill-finish stage—such as residual product left in tubing, overfilling, and scale mismatches—is often tolerated as an inevitable cost of doing business. However, these inefficiencies are largely driven by design choices rather than inherent operational flaws. When early-phase clinical batches inherit manufacturing paradigms optimized for large-scale production, relative losses escalate dramatically.

By adopting a strategic, "right-sized" manufacturing approach early in development, sponsors can align equipment, container selection, and process flows with actual program needs. This deliberate configuration minimizes hold-up volume without compromising strict sterility and quality standards. Ultimately, optimizing API utilization provides teams with greater operational flexibility, safeguarding timelines and preserving precious material for crucial studies.